NEWSpublisher 2007 :: AngloChinese Investments
SEARCH COMPANY
name:
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
employees:
from:    to: 
COMPANIES
APPROVALS
ACTIVITIES ENGAGED IN
R & D
CLINICAL TRIALS
NON CLINICAL & PRECLINICAL
CHEMISTRY-CONTRACT MANUFACTURE
TEST
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » China Aoxing Pharmaceutical Company, Inc. back to previous page show list

China Aoxing Pharmaceutical Company, Inc.

address: 444 Washington Boulevard,Suite 2424 Jersey City,NJ07310,USA

Tel:201-420-1075 Fax:201-420-1076

Add2:No.226 Zhonghua Northern Street,Shi Jiazhuang City,Hebei Province,China

Tel:+86-311-87751660 P.C.:050061
contact: US: Tel:201-420-1075 Fax:201-420-1076

ChiTel:+86-311-87751660 P.C.:050061na:


http://www.aoxingyaoye.com/
key person: Dr. Hui Shao Senior Vice President China Aoxing Pharmaceutical
Zhengjiang Yue is the founder and president of Hebei Aoxing Pharma, China Aoxing Pharma Group. He is military origin, junior college qualifications.Prior to founding AGP, he was the co

trunover in millions USD: 0
R & D turnover in millions USD: 0
NET profit: 0
year of financial results:
employees: 0

active in China: YES
partner in China: China Aoxing Pharmaceutical Company
(Hebei)
Add2:No.226 Zhonghua Northern Street,Shi Jiazhuang City,Hebei Province,China

SFDA approved: NO

Approvals:
GLP: NO
GMP: YES
AAALAC: NO
SEPA: NO

Activities engaged in:
Manufacture: YES
Active Pharmaceutical: YES
R&D: YES
Ingredients: YES
Western Generics: NO
TCM: NO

R & D:
Discovery: YES
Work Up (pilot to production): YES
Analysis: NO
Quality Control: NO
Stability: NO
Batch Release: NO

Clinical trials:
Run/Manage: NO
Data management: NO
Support Labs: NO

Non clinical & preclinical:
Animal Testing: GLP: NO
New materials Safety Assessment: NO
Pharmaceuticals: NO
Agrochemicals: NO
Industrial & Other Chemicals: NO
Non GLP - Discovery ADME: NO

Chemistry-contract manufacture:
Generics: NO
API: YES
Licensed Drugs: NO

test:
R&D: NO
 

China Aoxing Pharmaceutical Company, Inc. is a pharmaceutical company in China specializing in research, development, manufacturing and distribution of a variety of narcotics and pain management products. Headquartered in Shijiazhuang City, the pharmaceutical capital of China, outside of Beijing, the Company has the largest product pipeline and largest manufacturing facility (1.2 million sq. ft.) for highly regulated narcotic medicines, addressing a very under-served and fast-growing market in China. Its facility is one of the few GMP facilities licensed for narcotics medicines. The Company has two drugs on the market and has received China SFDA licenses for research and clinical development of seven more medications such as Oxycodone, Tilidine and Pholcodine. The Company is working closely with the Chinese government and SFDA to assure the strictly regulated availability to medical professionals of its narcotic drugs and pain medicines throughout China.

Aoxing was founded in 2000 with the total asset of $26 million. The campus occupies approximately 200,000 m2 including modern workshops to conduct R&D and manufacturing of chemical synthesis, as well as finished doses for pills, tablets, capsules, injections, oral solutions, buccal pellicles and transdermal patch products. We have developed a rich product pipeline focusing on narcotic and pain medicines, such as Shuanghuanglian capsules, Naloxone Hydrochloride API and injectables, Tilidine tablets and capsules, compound Tilidine tablets and capsules, Oxycodone Hydrochloride tablets and capsules, compound cold and cough solutions, Pholcoding raw material and solutions, Uprenorphine Naloxone sublingual tablets, etc. We started the first product launch in December 2006, and expect significant number of products entering the market in 2008. On April 24, 2007 China Aoxing signed a Letter of Intent to acquire Shijiazhuang Le Ren Tang Pharmaceutical Ltd ("LRT"). LRT is a pharmaceutical company organized under the laws of China specializing in the manufacturing and distribution of modernized Chinese traditional medicines, with a strong portfolio of pain management products. The transaction is expected to close by September 2007.


AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.